Genomic Testing

FOUNDATIONONE®LIQUID

FoundationOne Liquid is our next-generation liquid biopsy test for solid tumors utilizing circulating tumor DNA (ctDNA). This test may be considered to complement solid tissue results or when tissue is not ideal.
  • Cancer Type
    Solid Tumor
  • Sample Type
    Peripheral Whole Blood
  • Results Expected
    <2 weeks*

What is FoundationOne Liquid?

FoundationOne Liquid helps guide cancer care from a simple blood draw.

This liquid biopsy test provides targeted gene and microsatellite instability (MSI) results1 that can help direct therapy selection and clinical trial options for advanced-stage cancer patients using a minimally invasive sample type. By analyzing ctDNA with our comprehensive genomic profiling approach and providing expertly curated reports, FoundationOne Liquid empowers providers to make more informed clinical decisions even when tissue is not ideal.

Providers: Order a Kit

Overview

FoundationOne Liquid

  • 70

    genes interrogated

  • 99%

    PPV²

  • 99%

    sensitivity³

  1. A single liquid biopsy test that detects the 4 main classes of genomic alterations
  2. Provides a comprehensive genomic profile including resistance mutations or fusions in lung cancer4
  3. Now also includes MSI status and an expanded gene list including homologous recombination deficiency (HRD) genes to help guide therapy selection and clinical trials
  4. Requires only two 8.5mL tubes of blood

Please see footnotes below for information on PPV and sensitivity

Order FoundationOne Liquid

We make it easy for providers to order a kit for FoundationOne Liquid. When you’re ready to order a test, see the Provider Resources below.

Order a Kit

A doctor looking at the camera

Providers

FoundationOne Liquid is available through the online portal link below or by fax using our downloadable test requisition form. We have also provided additional PDF resources for those who want to learn more before ordering.

Order a Test

Patients

FoundationOne Liquid is ordered by your healthcare provider and we offer financial assistance for those who qualify. Download our form or apply online and speak with your healthcare provider today.

Apply Now

Questions? We’re here to help.

Call Foundation Medicine Client Services at (888) 988-3639 between 8:00 am ET and 8:00 pm ET, Monday through Friday. You can also send us an email and a representative will respond during regular business hours.

Contact Us

We have even more to offer.

Learn more about our other tests, FoundationOne CDx™, FoundationOne®Heme, or explore insights and trials or partnerships.

* Typical turnaround time from receipt of specimen is two weeks

1 MSI status will be reported for samples determined to have high microsatellite instability.

2 >99% PPV for all alterations, calculated as a weighted average of the PPV for each class of alteration, with the weighting based upon the frequency with which FoundationACT detects each class of alteration. The PPV for base substitutions, indels and rearrangements is >99% at >0.5% MAF. The PPV for copy number variations at ≥20% tumor fraction is 97.6%. Internal data on file.

3 >99% sensitivity for base substitutions, indels and rearrangements at >0.5% MAF. Sensitivity for copy number variations is >95% when the tumor fraction is ≥20%. Internal data on file.

4 Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SM. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Journal of Thoracic Oncology (2017)